The Company operates in one reportable segment. Sales to customers outside the U.S. represented 32%, 18% and 17% of total revenue for the years ended December 31, 2018, 2017 and 2016, respectively. As of December 31, 2018 and 2017, balances due from foreign customers were $23.4 million and $18.8 million, respectively.

The Company had sales to individual customers in excess of 10% of total revenue, as follows:



	Year ended December 31,
	2018		2017		2016
Customer:
A	19	%	20	%	15	%
B	13	%	13	%	13	%
C	12	%	21	%	16	%
	44	%	54	%	44	%

As of December 31, 2018 and 2017, accounts receivable from individual customers with balances due in excess of 10% of total accounts receivable totaled $33.3 million and $44.4 million, respectively.

The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands):



	Long-lived assets as of December 31,				Total revenue for the years ended December 31,
	2018		2017		2018		2017		2016
Domestic	$	72,569	$	59,833	$	354,895	$	227,611	$	158,244
Foreign	1,332		1,752		167,390		50,132		33,359
Total	$	73,901	$	61,585	$	522,285	$	277,743	$	191,603

Consolidated net revenues by product category are as follows (in thousands):



	Year ended December 31,
	2018		2017		2016
Rapid Immunoassay	$	183,160	$	165,099	$	121,416
Cardiac Immunoassay	266,524		47,030		—
Specialized Diagnostic Solutions	53,243		51,978		60,681
Molecular Diagnostic Solutions	19,358		13,636		9,506
Total revenues	$	522,285	$	277,743	$	191,603